ArriVent Biopharma claims best-in-class potential in gastrointestinal cancers for its new asset, but it’s not specifying the class. It’s possible the Phase 1-ready drug goes after claudin 18.2, a hot target for GI cancer drug research that recently welcomed its first FDA-approved therapy and is in pursuit by several companies.
AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenrep’s return to the market.
Novo Holdings led the Series A investment in Kivu Bioscience, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary.
Gilead Sciences' Trodelvy did not meet the main overall survival goal of its confirmatory Phase 3 test. The antibody drug conjugate was awarded accelerated approval for advanced urothelial carcinoma in 2021.
Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics. The MabCare ADC addresses PTK7, a protein found in many types of solid tumors.
GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.
Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021.
The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. AstraZeneca aims to open the facility in 2029.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies.
Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings.
The FDA expanded Enhertu’s approval to encompass advanced solid tumors positive for the HER2 cancer protein, regardless of tumor type. Analysts say the regulatory decision paves the way for similar broader approvals of other medications in the ADC cancer drug class.
Antibody specialist Genmab makes most of its money from drugs developed and commercialized by partners. Acquiring ProfoundBio brings antibody drug conjugates that Genmab can develop on its own as it continues diversifying its business beyond strategic alliances.
Ipsen is acquiring global rights to a Sutro Biopharma antibody drug conjugate for a target that is not yet hit by any FDA-approved drugs. Merck is among the companies pursuing this target, but Sutro claims its ADC could be first and best in this class.